- Home
- SLP vs AMRN Comparison
SLP vs AMRN Comparison
Compare SLP & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | AMRN |
|---|---|---|
| Founded | 1996 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 304.3M |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SLP | AMRN |
|---|---|---|
| Price | $16.57 | $14.97 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $24.00 | $12.00 |
| AVG Volume (30 Days) | ★ 385.1K | 79.8K |
| Earning Date | 04-09-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ 0.26 | N/A |
| Revenue | $59,577,000.00 | ★ $181,104,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.90 | $1.26 |
| P/E Ratio | $61.60 | ★ N/A |
| Revenue Growth | 10.52 | ★ 39.22 |
| 52 Week Low | $11.09 | $11.03 |
| 52 Week High | $34.01 | $20.90 |
Technical Indicators
Market Signals| Indicator | SLP | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 58.01 |
| Support Level | $16.26 | $14.65 |
| Resistance Level | $19.29 | $15.43 |
| Average True Range (ATR) | 0.86 | 0.66 |
| MACD | 0.15 | 0.09 |
| Stochastic Oscillator | 79.56 | 97.20 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.